GenREY: Building the Future of Regenerative Medicine

Why GenREY Exists

01.

Multi disciplinary, sovereign and high impactful regenerative medicine platform with a global vision.

02.

Evidence based research and clinical translation with an integration of AI-driven precision medicine.

03.

US?GCC dual-hub infrastructure aligned with Vision 2030

GenREY is building a single regenerative medicine global platform with an aim to repair, restore and rejuvenate the health to keep the individuals healthy, active and functional.

Our Mission

The Platform

Multiple Products in a Single Regenerative Systems Platform.

One integrated architecture. Every layer of medicine: discovery, translation, manufacturing, deployment. Connected.

AI Integration

Genomics, proteomics, and computational biology embedded across discovery, clinical prediction, and omics analysis.

Regenerative Medicine

Cellular repair, tissue regeneration, and organ biofabrication translated into deployable clinical therapeutics.

Translational Research

Bench-to-bedside pathways that move discoveries through validation, trials, and regulatory approval at speed.

Commercialization Engine

IP, regulatory strategy, and go-to-market infrastructure architected from day one. Not bolted on after launch.

Sovereign Collaboration

US?GCC dual-hub architecture aligned with Vision 2030 and national life-sciences priorities.

Manufacturing

Scalable cGMP-grade production engineered for regenerative therapeutics at population scale.

Clinical Deployment

Hospital, clinic, and physician-network channels designed to deliver therapies where care actually happens.

Ecosystem Architecture

Research, capital, talent, and policy partners coordinated into a single regenerative biotech corridor.

Strategic Initiatives

Six Strategic Initiatives.
One Connected Platform.

Each initiative advances a distinct frontier of regenerative science, unified through GenREY's integrated infrastructure.

Initiative 01

Hair Regeneration

iREY^TM, a multimodal platform combining a handheld delivery device with a proprietary bioactive serum ecosystem. The near-term commercialization flagship, targeting a global hair restoration market exceeding $20B.

Learn More

Initiative 02

Regenerative Therapeutics

Cell-assisted lipotransfer and bioactive scaffolding systems for clinical tissue reconstruction, addressing oncology-related repair, restorative medicine, and advanced aesthetic regeneration at clinical scale.

Learn More

Initiative 03

Precision Discovery

Follicle-selective androgen signaling modulators and biomarker-guided therapeutic targeting. Next-generation pharmacology engineered for superior precision, localized delivery, and significantly reduced systemic exposure.

Learn More

Initiative 04

Bioengineering

Device architecture, micro-fluidics, scaffold engineering, and organ-level biofabrication, driving the hardware and delivery infrastructure of the GenREY platform from bench to clinical deployment.

Learn More

Initiative 05

Longevity Systems

Hepatic regeneration, micro-organ validation, and progressive organogenesis research, building the long-horizon scientific foundation for organ-level repair and the next generation of human longevity medicine.

Learn More

Initiative 06

AI Biology

Genomics, proteomics, and AI-driven omics integration, anchoring GenREY's precision-medicine intelligence layer with computational biology and machine learning across every stage of discovery and clinical translation.

Learn More

Global Alignment

Built for Global Strategic Alignment

GenREY is structured as a sovereign-scale platform, designed for institutional alignment with the Kingdom of Saudi Arabia, the United Arab Emirates, and Qatar, anchored in Vision 2030 and the regional ambition to lead the next era of life sciences.

A Sovereign-Scale Platform

GenREY's architecture is purpose-built to advance regional priorities: domestic biotechnology capability, intellectual property co-ownership, and clinical workforce development, anchoring a permanent regional innovation corridor in regenerative medicine. We do not approach GCC participation as a market entry. We approach it as institutional partnership in the construction of long-term scientific and economic infrastructure.

Riyadh skyline, anchoring GenREY's institutional alignment with the Kingdom of Saudi Arabia

Vision 2030 Alignment

Direct contribution to the strategic ambitions of the Kingdom of Saudi Arabia and the broader GCC: life sciences leadership, knowledge economy development, and global scientific positioning.

Healthcare Innovation

Advancing regenerative medicine, precision therapeutics, and clinical translation infrastructure that compound into measurable improvements in healthcare delivery and patient outcomes across the region.

Scientific Infrastructure

Establishing manufacturing facilities, research collaboration networks, and institutional partnerships that anchor sovereign biotechnology capability within partner nations.

Talent Development

Clinical training, scientific workforce development, and institutional research programs designed to build a highly skilled domestic life sciences workforce over the long term.

Economic Diversification

Co-ownership of globally relevant intellectual property, domestic manufacturing and commercialization, and establishment of new high-value knowledge industries, diversifying the regional economic base.

Sustainable Biotech Ecosystems

Building permanent institutional and industrial infrastructure for regenerative medicine: research, manufacturing, clinical deployment, and commercial translation. Engineered to last beyond any single program or initiative.

FAQ

Common Questions

Is GenREY a biotechnology company?

GenREY is more than a biotechnology company. It is a platform designed to connect scientific innovation, clinical translation, manufacturing, and commercialization into one ecosystem.

What areas does GenREY focus on?

The platform operates across regenerative medicine, drug discovery, tissue engineering, advanced therapeutics, and organ bioengineering.

Who can partner with GenREY?

Healthcare organizations, research institutions, biotechnology companies, investors, strategic partners, and government stakeholders.

Where is GenREY based, and where does it operate?

GenREY operates through a dual-hub architecture, anchored in the United States for scientific infrastructure and capital markets, and in the Kingdom of Saudi Arabia for sovereign partnership and regional deployment aligned with Vision 2030.

How do I begin a conversation with GenREY?

Reach out directly at [email protected]. Strategic briefings are available on a selective basis. We recommend introducing your organization and area of interest in your first message.

Leadership

Built by Leaders in Medicine,
Science, and Biotechnology

Led by physician-scientists, researchers, and biotechnology operators working across regenerative medicine, drug discovery, tissue engineering, and advanced healthcare innovation.

Executive Leadership Team

The Executive Leadership Team guides GenREY's scientific vision, operational execution, strategic partnerships, commercialization pathways, and long-term institutional growth.

Dr. Jerry Lorren Dominic, MD

Co-Founder, President & Chief Executive Officer

View Bio

Mohammad Yasar Qureshi

Co-Founder & Chief Operating Officer

View Bio

Dr. Sudheer Kumar Ravuri, PhD

Chief Scientific Officer & Founding Scientific Advisor ? Chairman, Board of Directors

View Bio

Scientific Advisory Committee

Experienced medical and scientific leaders providing advisory guidance across regenerative medicine, translational research, and clinical development.

Dr. Daniel A. Romanelli, MD

Senior Advisor

Advisory guidance across clinical strategy and industry relations

Dr. Moses Raj, MD

Scientific Advisory Committee Member

Advisory guidance across regenerative medicine and clinical development

Dr. Aaron H. Wolfson, MD

Scientific Advisory Committee Member

Advisory guidance across innovation and technology development

Dr. Subhash Chauhan, PhD, LPC

Scientific Advisory Committee Member

Advisory guidance across translational research and platform strategy

Dr. Patricia Byers, MD

Scientific Advisory Committee Member

Advisory guidance across clinical development and platform strategy

Program Directors

GenREY's Program Directors support the development, coordination, and advancement of key scientific, clinical, and operational programs across the platform.

Dr. Mohammad Shabir Hussain, PhD

Senior Scientist

Omics, computational biology, and molecular science driving GenREY's data-led research programs

Kaushik Sreerama Reddy, MBBS

Program Management Officer

Program coordination, operational management, and cross-functional platform execution

Dr. Matthew Witkin, MD

Program Director

Oncology research and scientific strategy advancing GenREY's clinical translation programs

Dr. Adam Bender-Heine, MD

Program Director

Head and neck surgery, facial reconstruction, and regenerative biotechnology translation

Dr. Jeffrey James Skubic, DO

Program Director

Trauma surgery, surgical critical care, and clinical program development

Dr. Paul Anthony Berry, MD

Program Director

Aesthetic medicine, reconstructive surgery, and biotechnology-driven clinical innovation

Dr. Mohammad Waqas Khan, MD

Program Director

Clinical medicine and translational program development across GenREY's therapeutic pipeline

Dr. Bindiya Sachdev, PhD

Program Director

Life sciences communications, proteomics research, and biotechnology program strategy

Dr. Swathi Godugu, MD

Program Director

Internal medicine, critical care research, and evidence-based clinical program development

View full team

Engineering the Future of Regenerative Systems.

Multiple Products in a Single Regenerative Systems Platform.